Dr Reddy's Completes Major Healthcare Brand Acquisition

Dr Reddy's Laboratories has finalized the acquisition of Haleon plc's global portfolio of consumer healthcare brands in the Nicotine Replacement Therapy (NRT) category. The acquisition, costing GBP 458 million, extends Dr Reddy's consumer healthcare reach and includes popular brands like Nicotinell, Nicabate, Thrive, and Habitrol.

Dr Reddy's Laboratories announced on Monday that its subsidiary in Switzerland has completed the acquisition of Haleon plc's global portfolio of consumer healthcare brands outside of the US, specifically in the Nicotine Replacement Therapy (NRT) sector.

The transaction was executed through the purchase of shares in Northstar Switzerland SARL, a Haleon group entity, for an upfront cash consideration of GBP 458 million, according to a regulatory filing by the Hyderabad-based pharmaceutical giant.

The acquired assets, which include Nicotinell, Nicabate, Thrive, and Habitrol, will bolster Dr Reddy's consumer healthcare business, enhancing its offerings across various global markets including Europe, Asia, and Latin America.

(With inputs from agencies.)